AYTU Aytu BioPharma, Inc. - Fundamental Analysis
NEUTRAL
Sign in to save
Save this symbol to a watchlist or track a position.
AYTU Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
Current Price
Live
$2.7
Analyst Target
$9.33
+245.7%
Upside
52W High
$3.07
52W Low
$0.95
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
65%
Analysis Accuracy
The Advanced Deterministic Scorecard shows a weak Piotroski F-Score of 4/9, indicating borderline financial health, and the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite unprofitability (ROE: -50.23%, Profit Margin: -20.52%) and declining revenue (YoY -16.20%), the stock has seen strong short-term price momentum (+61.7% 1Y) and a bullish analyst recommendation (strong_buy) with a high target price of $9.33. High gross margins (67.56%) and improving quarterly earnings surprises (avg +98.68% last 4 quarters) suggest operational progress, but weak cash visibility, leverage (Debt/Equity: 1.23), and inconsistent earnings history remain concerns. The stock trades at a forward P/E of 15.88, below sector average, potentially reflecting skepticism around sustainability.
Key Strengths
High gross margin (67.56%) indicates strong pricing power or low production costs
Recent earnings surprises significantly positive (avg +98.68% last 4 quarters)
Analyst consensus is strong_buy with a high target price ($9.33) implying 245% upside
Forward P/E of 15.88 is below sector average (220.68), suggesting relative value
Recent price momentum is positive (+61.7% over 1 year)
Key Risks
Piotroski F-Score of 4/9 indicates weak financial health and poor profitability
Profitability remains negative (Profit Margin: -20.52%, ROE: -50.23%)
Revenue declining YoY (-16.20%) and limited financial transparency (missing cash/debt data)
High earnings volatility and inconsistent track record (e.g., -3600% surprise in 2023)
Leverage is elevated with Debt/Equity ratio of 1.23 and no Altman Z-Score to assess bankruptcy risk
AI Fair Value Estimate
Based on comprehensive analysis
$9.33
+245.6% above current price
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare AYTU against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning AYTU from our newsroom.
Newest → oldest
No matching news yet.